Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG:1349)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.070
+0.040 (1.32%)
Mar 10, 2026, 4:08 PM HKT
15.85%
Market Cap 7.53B
Revenue (ttm) 763.16M
Net Income (ttm) -175.20M
Shares Out 1.04B
EPS (ttm) -0.17
PE Ratio n/a
Forward PE n/a
Dividend 0.07 (2.24%)
Ex-Dividend Date n/a
Volume 1,021,000
Average Volume 2,015,950
Open 3.100
Previous Close 3.030
Day's Range 3.050 - 3.110
52-Week Range 2.130 - 5.290
Beta 0.12
RSI 46.51
Earnings Date Mar 31, 2026

About HKG:1349

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clinical trials for tumors; Trop2-BB05 ADC that is in Phase I clinical trial for tumors; DLL3-BB05 ADC, which is in phase I clinical trial for tumors; and H... [Read more]

Sector Healthcare
Founded 1996
Employees 899
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1349
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.